REGN Cemdisiran: gMG PDUFA vs Vyvgart's $4.2B

Regeneron closed Tuesday at $833.56 with a market cap near $85 billion. When a company that size files a drug, the honest question is not whether the FDA will approve it. The question is whether the approval moves the stock. Cemdisiran, Regeneron’s first RNAi therapy, hits its PDUFA date in November 2026. The answer is blunt: the approval is likely, the data are best in class, and the stock that moves is not Regeneron’s. It is Alnylam’s.

Cemdisiran is a GalNAc-conjugated small interfering RNA that silences complement factor 5, or C5, the protein that drives the immune attack on the neuromuscular junction in myasthenia gravis. Regeneron licensed it from Alnylam, the company that built the RNAi platform and still collects milestones and royalties on the program. Read the RNAi versus antisense platform war for why that licensing relationship matters more than the drug itself. Here is the first thing to understand: generalized myasthenia gravis is already a three-way mechanism war, and cemdisiran is the fourth entrant.

Vyvgart (efgartigimod) from argenx blocks FcRn, lowering the IgG autoantibodies that cause the disease. It generated $4.2 billion in 2025 sales, up 90% year over year, and pushed argenx to its first full-year profit. That $4.2 billion is the number every gMG challenger is measured against, and argenx now carries a $63.6 billion market cap on the back of it. Ultomiris (ravulizumab) from AstraZeneca is a C5 antibody dosed intravenously every eight weeks, already approved in gMG before it stumbled in a recent Phase 3 miss (more on Ultomiris here). Cemdisiran hits the same C5 target as Ultomiris but with an RNAi mechanism and subcutaneous dosing every twelve weeks. That is the bull thesis in one sentence: the first quarterly, under-the-skin complement therapy in gMG.

The disease is bigger than most investors realize. Roughly 85,000 Americans live with myasthenia gravis, and about 85% of them progress from ocular symptoms to the generalized form that affects breathing, swallowing, and mobility. Vyvgart’s 90% growth is proof the market is nowhere near saturated; it is still expanding as patients move off older therapies.

The data back the thesis. The Phase 3 NIMBLE trial (NCT05070858), published in The Lancet on May 2, 2026, randomized 284 adults across 86 centers in 13 countries. Patients were positive for anti-AChR or anti-LRP4 antibodies with an MG-ADL score of 6 or higher. The trial ran four arms: cemdisiran 600 mg every twelve weeks, pozelimab 200 mg every four weeks, a combination of the two, and placebo. On the primary endpoint, change in the MG-ADL score at week 24, cemdisiran delivered a least-squares mean improvement of 4.5 points versus 2.2 for placebo, a placebo-adjusted difference of 2.3 points (p = 0.0005). On the key secondary endpoint, the QMG muscle-function score, cemdisiran improved 4.2 points versus 1.5 for placebo, a 2.8 point adjusted difference (p = 0.0015).

The speed is what separates this from the C5 antibodies. Cemdisiran patients showed a 2.5 point MG-ADL improvement within two weeks, before most biologics are expected to act, and the benefit did not wane between doses through week 24. The combination arm, by contrast, improved MG-ADL by 4.0 points for a 1.7 point placebo-adjusted difference (p = 0.0086). Monotherapy was numerically better than the combo. That is the rare case where adding a second drug adds nothing, and it is a quiet point in favor of the RNAi doing the heavy lifting on its own.

Those effect sizes matter because there is a clear benchmark. Approved C5 inhibitors have shown placebo-adjusted MG-ADL improvements ranging from 1.6 to 2.1 points in their registrational trials. Cemdisiran’s 2.3 point delta sits at the top of that range, and its 2.8 point QMG delta sits near the top. Put another way: 76.6% of cemdisiran patients hit a clinically meaningful 3 point MG-ADL improvement versus 44.1% on placebo. On QMG, 48.4% hit a 5 point improvement versus 19% on placebo.

The safety profile is clean by complement-inhibitor standards. Treatment-emergent adverse events ran 69.2% for cemdisiran versus 77.1% for placebo. Infection rates were 27% versus 40%. There were no meningococcal infections and no deaths in the double-blind period. One death from pneumonia occurred in the extension phase in a patient with significant comorbidities on background immunosuppressants. That single event is the data point the FDA will stare at hardest.

The regulatory path is set. Regeneron’s NDA was accepted in June 2026 under Priority Review, with the company burning a priority review voucher to compress the timeline. The target action date is November 2026, and the EMA is reviewing in parallel with a European Commission decision expected in the second half of 2027. Note the label question already flagged by analysts: NIMBLE allowed patients to continue background immunosuppressants, so the FDA will decide whether to restrict the label to monotherapy or permit concurrent use.

Now the competitive math. Vyvgart’s $4.2 billion franchise is the benchmark, and Ultomiris already holds a gMG label as an IV every-eight-weeks option. The realistic prize for a quarterly subcutaneous RNAi is the convenience segment: patients who want deep, durable complement suppression without an infusion chair or a weekly self-injection. Cemdisiran is on track for $1 billion to $2 billion in peak sales. That is a real drug, but it is 7% to 14% of Regeneron’s $14.3 billion in 2025 revenue.

The valuation comparison sharpens the point. Regeneron’s $85 billion market cap works out to roughly 6x its $14.3 billion revenue base, a premium earned by Dupixent and Eylea HD, not by a $1.5 billion niche asset. Argenx commands $63.6 billion on $4.2 billion of product sales, roughly 15x, because Vyvgart is still growing 90%. Alnylam sits in the middle at $31.6 billion. The market is paying argenx a growth multiple for a single drug and paying Regeneron a franchise multiple for a portfolio. Cemdisiran does not move either multiple. It is a 7% to 14% revenue add for Regeneron and a thesis-confirming data point for Alnylam. That asymmetry is the trade.

The move belongs to Alnylam. The bull case is not about this one royalty stream. It is that a gMG approval validates siRNA beyond the rare hereditary disease niche Alnylam built its reputation on, the ATTR amyloidosis and primary hyperoxaluria programs that anchor the franchise and now stretch into hypertension (see the nucapsiran primer). Every new therapeutic-area win makes the platform multiple stickier. A dosing-interval moat is exactly the kind of advantage that translates across disease areas, and cemdisiran is the cleanest demonstration of it yet. The asset also has optionality beyond gMG: Regeneron is running cemdisiran in Phase 3 for paroxysmal nocturnal hemoglobinuria and geographic atrophy, two more complement-mediated markets. For a large-cap that is pipeline depth; for Alnylam each additional indication is another royalty trigger. That is why ALNY is the preferable holding into this catalyst.

The risks are specific, not generic. First, the label. If the FDA restricts cemdisiran to monotherapy, the addressable market shrinks against Vyvgart, which is used broadly across the gMG population. Second, the complement safety overhang. One pneumonia death in a comorbid patient is explainable, but complement inhibition carries an inherent meningococcal infection risk that requires vaccination and monitoring. Third, competition is not standing still. Argenx is pushing Vyvgart Hytrulo, its subcutaneous formulation, into the same convenience segment, and the FcRn franchise keeps expanding into new autoimmune indications (see the Alkivia analysis).

Verdict: buy the platform, not the single asset. Cemdisiran clears the November PDUFA with high odds, but Regeneron’s stock will barely notice. For Alnylam, the approval is one more brick in a platform wall that keeps converting rare-disease skeptics into believers. Position accordingly: if you want the RNAi thesis, own ALNY in size; treat REGN as a Hold where cemdisiran is a free option, not a reason to buy.